NCT07929298
A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage Change in Body Weight
Timeframe: Baseline, week 24
Secondary (15)
Percentage of Participants with ≥5% of Body Weight Loss
Percentage of Participants with ≥10% of Body Weight Loss
Percentage of Participants with ≥15% of Body Weight Loss
Absolute Change in Body Weight
Change in Body Mass Index (BMI)
Show 10 moreShow less
Change in blood pressure
Change in other body measurements
Change in lipid profile
Change in fasting blood glucose (FBG)
Change in HbA1c
Change in fasting insulin
Change in blood uric acid
Change in liver enzymes
Adverse events
Plasma Concentration of Ecnoglutide
Arms and interventions
oral ecnoglutide dose 1Experimental
once daily from week1 to week 8, then once weekly from week 9 to week 24
oral ecnoglutide dose 2Experimental
once daily from week1 to week 8, then once weekly from week 9 to week 24
oral ecnoglutide dose 3Experimental
once daily from week1 to week 12, then once weekly from week 13 to week 24
PlaceboPlacebo comparator
once daily from week1 to week 8 or week 12, then once weekly from week 9 or week 13 to week 24
oral ecnoglutide dose 4Experimental
once daily from week1 to week 12, then once weekly from week 13 to week 24
Drugs: ecnoglutide tablet, placebo with matching dosage
Sites
1 site in 1 country
- The First Affiliated Hospital of Henan University of Science & TechnologyLuoyang, Henan, China